美固科技控股(08349.HK):潛在買方已大致完成盡職審查
格隆匯5月14日丨美固科技控股(08349.HK)發佈公告,有關售股股東與潛在買方就售股股東可能向潛在買方出售其所持的待售股份的可能交易而訂立諒解備忘錄。於該公告日期,潛在買方已大致完成對集團進行的盡職審查,而訂約各方之間仍在磋商正式協議的條款。由於COVID-19疫情所導致的中國內地封鎖措施已逐漸解除,因此預期盡職審查快將完成,而訂約各方將在適當時候就正式協議的條款達成共識。
於該公告日期,出售事項因若干程序事宜而尚未完成。由於疫情所導致的旅行限制及隔離安排尚未撤銷,目前需要更多時間處理程序事宜。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.